CDEK
← All drugs Report issue

roxadustat

Small moleculeexperimental

Roxadustat, sold under the brand name Evrenzo, is an anti-anemia medication. Roxadustat is a HIF prolyl-hydroxylase inhibitor that increases endogenous production of erythropoietin and stimulates production of hemoglobin and red blood cells. It was investigated in clinical trials for the treatment of anemia caused by chronic kidney disease (CKD). It is taken by mouth. The drug was developed by FibroGen, in partnership with AstraZeneca. — Wikipedia

Clinical trial activity

63 trials · 24 clinical orgs · 0 marketing orgs

Phase 1
15
Phase 2
39
Phase 3
26
Phase 4
9

Earliest trial started Nov 1, 2008 (NCT00761657)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1nc(C(=O)NCC(=O)O)c(O)c2ccc(Oc3ccccc3)cc12
Mol. weight
352.35 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • asp1517
  • asp1517
  • asp1517
  • fg-4592
  • fg-4592
  • fg-4592
  • roxadustat
  • roxadustat
  • roxadustat
  • roxadustat
  • roxadustat

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07162090Phase 4Sep 10, 2025Tianjin Medical University
NCT07045155Phase 4Aug 1, 2025Jiangsu Hansoh Pharmaceutical Co., Ltd., People's Liberation Army of China
NCT06903559Phase 1/Phase 2 (Phase 2)Apr 15, 2025Mansoura University
NCT06917950Phase 1/Phase 2 (Phase 2)Apr 15, 2025Mansoura University
NCT06772272Phase 3Nov 10, 2024Zhejiang University
NCT05810311Phase 2Jan 1, 2024County of Stockholm
NCT05970172Phase 3Nov 20, 2023Astellas
NCT06006949Phase 4Aug 31, 2023Chinese Academy of Medical Sciences
NCT06020833Phase 1/Phase 2 (Phase 2)Aug 31, 2023Chinese Academy of Medical Sciences
NCT06115421Phase 4May 24, 2023Alexandria University
NCT05691257Phase 4Feb 1, 2023Peking University
NCT05301517Phase 3Mar 16, 2022FibroGen
NCT05010460Phase 2Sep 30, 2021Chinese Academy of Medical Sciences, Peking University
NCT04925661Phase 1Sep 29, 2021Government of China, Sunshine Lake Pharma Co., Ltd.
NCT05053893N/ASep 22, 2021Qingdao University
NCT04925011Phase 3Sep 1, 2021Zhejiang University
NCT04803864Phase 2Jun 10, 2021Jiao Tong University
NCT04655027Phase 4Dec 25, 2020AstraZeneca, Chinese Academy of Medical Sciences, Parexel
NCT04621331Phase 3Nov 30, 2020AstraZeneca, FibroGen
NCT04484857Phase 3Jul 17, 2020AstraZeneca, FibroGen
Showing 20 of 63 trials
Page 1 / 4

Organizations

Research & Development (24)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
FibroGenFor profit402142008
AstellasFor profit262232009
AstraZenecaFor profit12332012
Chinese Academy of Medical SciencesAcademic/Hospital4322020
Peking UniversityAcademic/Hospital4222011
Zhejiang UniversityAcademic/Hospital3222011
Jiao Tong UniversityAcademic/Hospital2112011
Mansoura UniversityAcademic/Hospital2212025
Alexandria UniversityAcademic/Hospital1112023
Capital Medical UniversityAcademic/Hospital1012020
Central South UniversityAcademic/Hospital1112019
Chang Zheng HospitalAcademic/Hospital1012011
County of StockholmGovernment1112024
Denver Nephrologists, P.C.Academic/Hospital1012014
Government of ChinaGovernment1012021
Jiangsu Hansoh Pharmaceutical Co., Ltd.For profit1012025
ParexelFor profit1012020
People's Liberation Army of ChinaGovernment1112025
Qingdao UniversityAcademic/Hospital1112021
Shenzhen UniversityAcademic/Hospital1012011
24 organizations
Page 1 / 2